<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3417e20b-604b-3cdd-e063-6394a90ac707"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Cefaclor Capsules USP</title>
   <effectiveTime value="20250501"/>
   <setId root="2f61354e-bcb0-41aa-955f-51eabc11387b"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="781047246"/>
            <name>Carlsbad Technology, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="656108149"/>
                  <name>Yung Shin Pharmaceutical Industrual Co., Ltd.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="656108149"/>
                        <name>Yung Shin Pharmaceutical Industrial Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="61442-171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="61442-172" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3419fdf4-afbb-6382-e063-6294a90a3af6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61442-171" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefaclor</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefaclor</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="MD83SFE959" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TERT-BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="69K7K19H4L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFACLOR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3Z6FS3IK0K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFACLOR ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-171-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-171-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-171-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065146" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080731"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>BLUE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText>PINK</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>CAPSULE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KRC
</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61442-172" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefaclor</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefaclor</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="MD83SFE959" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TERT-BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="69K7K19H4L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFACLOR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3Z6FS3IK0K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFACLOR ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-172-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-172-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61442-172-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065146" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080731"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>BLUE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText>ORANGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>CAPSULE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="23" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KRC500
</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="3417e20b-604c-3cdd-e063-6394a90ac707"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsule and other antibacterial drugs, Cefaclor Capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20150909"/>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="3417ea10-b47c-3fea-e063-6394a90a76ce"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Cefaclor, USP is a semisynthetic cephalosporin antibiotic for oral administration. It is chemically designated as 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. The chemical formula for cefaclor is C
  <sub>15</sub>H
  <sub>14</sub>ClN
  <sub>3</sub>O
  <sub>4</sub>S • H
  <sub>2</sub>O and the molecular weight is 385.82.
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L2a84afd1-c78a-4cd6-9133-4a08d75aedcc"/>
                  </paragraph>
                  <paragraph>Each 250-mg capsule contains cefaclor monohydrate equivalent to 250 mg (0.68 mmol) of anhydrous cefaclor and inactive ingredients: magnesium stearate, sodium starch glycolate, lactose monohydrate, talc. The 250 mg capsule shell contains gelatin, titanium dioxide, FD &amp; C Blue No. 1, FD &amp; C Red No. 3, and imprinting ink components: shellac, strong ammonia solution, potassium hydroxide, black iron oxide, .dehydrated alcohol, isopropyl alcohol, butyl alcohol and propylene glycol.</paragraph>
                  <paragraph>Each 500-mg capsule contains cefaclor monohydrate equivalent to 500 mg (1.36 mmol) of anhydrous cefaclor and inactive ingredients: magnesium stearate, sodium starch glycolate, lactose monohydrate, talc. The 500 mg capsule shell contains gelatin, titanium dioxide, FD &amp; C Blue No. 1, FD &amp; C Red No. 3, FD &amp; C Yellow No. 6, FD &amp; C Red No. 40, and imprinting ink components: shellac, strong ammonia solution, titanium dioxide, FD &amp; C Blue No. 1 aluminum lake, dehydrated alcohol, isopropyl alcohol, butyl alcohol and propylene glycol.</paragraph>
               </text>
               <effectiveTime value="20150909"/>
               <component>
                  <observationMedia ID="L2a84afd1-c78a-4cd6-9133-4a08d75aedcc">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cef0g-0000-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="3417e20b-604e-3cdd-e063-6394a90ac707"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three fourths to 1 hour later. Following administration of 250-mg, 500-mg, and 1-g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL respectively were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250-mg, 500-mg and 1-g doses were approximately 600, 900 and 1,900 mc
 
  <content styleCode="italics"/>g/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%.

 </paragraph>
               </text>
               <effectiveTime value="20150910"/>
               <component>
                  <section ID="s4">
                     <id root="3417f05c-5521-b51c-e063-6294a90a69f0"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">Mechanism of Action</content>
                           </content>
                           <br/>
As with other cephalosporins, the bactericidal action of cefaclor results from inhibition of cell-wall synthesis.
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Mechanism of Resistance</content>
                           </content>
                        </paragraph>
                        <paragraph>Resistance to cefaclor is primarily through hydrolysis of beta-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. 
  <content styleCode="italics">Pseudomonas</content>spp 
  <content styleCode="italics">., Acinetobacter calcoaceticus </content>and most strains of 
  <content styleCode="italics">Enterococi </content>(
  <content styleCode="italics">Enterococcus faecalis,</content>group D streptococci), 
  <content styleCode="italics">Enterobacter </content>spp 
  <content styleCode="italics">.,</content>indole-positive 
  <content styleCode="italics">Proteus, Morganella morganii </content>(formerly 
  <content styleCode="italics">Proteus morganii</content>), 
  <content styleCode="italics">Providencia rettgeri </content>(formerly 
  <content styleCode="italics">Proteus rettgeri</content>) and 
  <content styleCode="italics">Serratia </content>spp. are resistant to cefaclor. Cefaclor is inactive against methicillin-resistant staphylococci. β-lactamase-negative, ampicillin-resistant strains of 
  <content styleCode="italics">H. influenzae </content>should be considered resistant to cefaclor despite apparent 
  <content styleCode="italics">in vitro </content>susceptibility to this agent.
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Antibacterial Activity</content>
                           </content>
                           <br/>
Cefaclor has been shown to be active against most strains of the following microorganisms both 
  <content styleCode="italics">in vitro </content>and in clinical infections as described in the INDICATIONS AND USAGE section.
 </paragraph>
                        <paragraph>
                           <br/>
                           <content styleCode="underline">Gram-positive Bacteria</content>
                           <br/>
                           <content styleCode="underline">
                              <content styleCode="italics">Staphylococcus aureus </content>(methicillin susceptible only) 
  </content>
                           <br/>
                           <content styleCode="underline">Coagulase negative staphylococci (methicillin susceptible only)</content>
                           <br/>
                           <content styleCode="italics">Streptococcus pneumoniae</content>
                           <br/>
                           <content styleCode="italics">Streptococcus pyogenes </content>(group A β-hemolytic streptococci)
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gram-negative Bacteria</content>
                           <br/>
                           <content styleCode="italics">Escherichia coli</content>
                           <br/>
                           <content styleCode="italics">Haemophilus influenzae </content>(excluding β-lactamase-negative, ampicillin-resistant strains)
  <br/>
                           <content styleCode="italics">Klebsiella </content>spp.
  <br/>
                           <content styleCode="italics">Proteus mirabilis</content>
                        </paragraph>
                        <paragraph>The following 
  <content styleCode="italics">in vitro</content> data are available, 
  <content styleCode="bold">but their clinical significance is unknown</content>. At least 90 percent of the following bacteria exhibit an 
  <content styleCode="italics">in vitro </content>minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint of cefaclor. However, the safety and effectiveness of cefaclor in treating clinical infections due to these bacteria has not been established in adequate and well-controlled trials.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gram-negative Bacteria</content>
                           <br/>
                           <content styleCode="italics">Citrobacter diversus</content>
                           <br/>
                           <content styleCode="italics">Moraxella catarrhalis</content>
                           <br/>
                           <content styleCode="italics">Neisseria gonorrhoeae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Anaerobic Bacteria</content>
                           <br/>
                           <content styleCode="italics">Bacteroides </content>spp.
  <br/>
                           <content styleCode="italics">Peptococcus </content>spp.
  <br/>
                           <content styleCode="italics">Peptostreptococcus </content>spp.
  <br/>
                           <content styleCode="italics">Propionibacterium acnes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Susceptibility Testing</content>
                           </content>
                           <br/>
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
 </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20150910"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="34180158-bdbf-c045-e063-6294a90ab71e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Otitis media</content> caused by 
  <content styleCode="italics">Streptococcus pneumoniae, Haemophilus influenzae,</content>staphylococci, and 
  <content styleCode="italics">Streptococcus pyogenes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: </content>β-lactamase-negative, ampicillin-resistant (BLNAR) strains of 
  <content styleCode="italics">Haemophilus influenzae </content>should be considered resistant to cefaclor despite apparent 
  <content styleCode="italics">in vitro </content>susceptibility of some BLNAR strains.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lower respiratory tract infections,</content> including pneumonia, caused by 
  <content styleCode="italics">Streptococcus pneumoniae, Haemophilus influenzae,</content>and 
  <content styleCode="italics">Streptococcus pyogenes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: </content>β-lactamase-negative, ampicillin-resistant (BLNAR) strains of 
  <content styleCode="italics">Haemophilus influenzae </content>should be considered resistant to cefaclor despite apparent 
  <content styleCode="italics">in vitro </content>susceptibility of some BLNAR strains.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pharyngitis and Tonsillitis,</content> caused by 
  <content styleCode="italics">Streptococcus pyogenes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note:</content>Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Urinary tract infections,</content> including pyelonephritis and cystitis, caused by 
  <content styleCode="italics">Escherichia coli, Proteus mirabilis, Klebsiella </content>spp 
  <content styleCode="italics">.,</content>and coagulase-negative staphylococci
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Skin and skin structure infections</content> caused by 
  <content styleCode="italics">Staphylococcus aureus and Streptococcus pyogenes</content>
                  </paragraph>
                  <paragraph>Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsule and other antibacterial drugs, Cefaclor Capsule should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
               </text>
               <effectiveTime value="20150909"/>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="3417e20b-6051-3cdd-e063-6394a90ac707"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATION</title>
               <text>
                  <paragraph>Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.</paragraph>
               </text>
               <effectiveTime value="20120629"/>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="34180da5-16e9-5339-e063-6394a90a7d6e"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">IF AN ALLERGIC REACTION TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</content>
                  </paragraph>
                  <paragraph>Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefaclor, and has ranged in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.</content>
                  </paragraph>
                  <paragraph>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by 
  <content styleCode="italics">Clostridium difficile </content>is one primary cause of antibiotic-associated colitis.
 </paragraph>
                  <paragraph>After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug effective against 
  <content styleCode="italics">C. difficile.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20120629"/>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="3417e20b-6053-3cdd-e063-6394a90ac707"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20150910"/>
               <component>
                  <section ID="s12">
                     <id root="3417e20b-6054-3cdd-e063-6394a90ac707"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Prescribing cefaclor in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <paragraph>Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.</paragraph>
                        <paragraph>Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. It should be recognized that a positive Coombs' test may be due to the drug, e.g., in hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition.</paragraph>
                        <paragraph>Cefaclor should be administered with caution in the presence of markedly impaired renal function. Since the half-life of cefaclor in anuria is 2.3 to 2.8 hours, dosage adjustments for patients with moderate or severe renal impairment are usually not required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.</paragraph>
                        <paragraph>As with other β-lactam antibiotics, the renal excretion of cefaclor is inhibited by probenecid.</paragraph>
                        <paragraph>Antibiotics, including cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="3417e20b-6055-3cdd-e063-6394a90ac707"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be counseled that antibacterial drugs including cefaclor should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefaclor is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefaclor or other antibacterial drugs in the future.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="34181d30-3484-c946-e063-6294a90adbd6"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Patients receiving cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest
  <sup>® </sup>tablets.
 </paragraph>
                        <paragraph>There have been reports of increased anticoagulant effect when cefaclor and oral anticoagulants were administered concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="3417e20b-6057-3cdd-e063-6394a90ac707"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies have not been performed to determine potential for carcinogenicity, mutagenicity, or impairment of fertility.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="34182336-e86d-d34f-e063-6294a90a5742"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy ─ Teratogenic Effects ─ Pregnancy Category B</title>
                     <text>
                        <paragraph>Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20150910"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="3417e20b-6059-3cdd-e063-6394a90ac707"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>The effect of cefaclor on labor and delivery is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="3417e20b-605a-3cdd-e063-6394a90ac707"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Small amounts of cefaclor have been detected in mother's milk following administration of single 500-mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20150910"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="3417e20b-605b-3cdd-e063-6394a90ac707"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="3417e20b-605c-3cdd-e063-6394a90ac707"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Of the 3703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney (see
 
  <content styleCode="bold">
                              <linkHtml href="#s3">CLINICAL PHARMACOLOGY</linkHtml>
                           </content>), and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful in monitor renal function (see
 
  <content styleCode="bold">
                              <linkHtml href="#s26">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20150910"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="3418527b-c97b-0189-e063-6294a90a1f6d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse effects considered to be related to therapy with cefaclor are listed below:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity </content>reactions have been reported in about 1.5% of patients and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients.
 </paragraph>
                  <paragraph>Cases of 
  <content styleCode="bold">serum-sickness-like </content>reactions have been reported with the use of cefaclor. These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied by arthritis/arthralgia, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a 
  <content styleCode="bold">serum-sickness-like </content>reaction. While further investigation is ongoing, 
  <content styleCode="bold">serum-sickness-like </content>reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric patients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.
 </paragraph>
                  <paragraph>More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including angioedema, asthenia, edema (including face and limbs), dyspnea, paresthesias, syncope, hypotension, or vasodilatation. Anaphylaxis may be more common in patients with a history of penicillin allergy.</paragraph>
                  <paragraph>Rarely, hypersensitivity symptoms may persist for several months.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal </content>symptoms occur in about 2.5% of patients and include diarrhea (1 in 70).
 </paragraph>
                  <paragraph>Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (see 
  <content styleCode="bold">
                        <linkHtml href="#s10">WARNINGS</linkHtml>
                     </content>). Nausea and vomiting have been reported rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Other </content>effects considered related to therapy included eosinophilia (1 in 50 patients), genital pruritus, moniliasis or vaginitis (about 1 in 50 patients), and, rarely, thrombocytopenia or reversible interstitial nephritis.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Causal Relationship Uncertain –</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">CNS</content> ─ Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, and somnolence have been reported.
 </paragraph>
                  <paragraph>Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatic</content> ─ Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40).
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hematopoietic</content> ─ As has also been reported with other β-lactam antibiotics, transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia, aplastic anemia, agranulocytosis, and reversible neutropenia of possible clinical significance.
 </paragraph>
                  <paragraph>There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and Coumadin
  <sup>® </sup>concomitantly.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal</content> ─ Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).
 </paragraph>
               </text>
               <effectiveTime value="20150910"/>
               <component>
                  <section ID="s22">
                     <id root="3417e20b-605e-3cdd-e063-6394a90ac707"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cephalosporin-class Adverse Reactions</title>
                     <text>
                        <paragraph>In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: fever, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, hemorrhage, false positive test for urinary glucose, elevated bilirubin, elevated LDH, and pancytopenia.</paragraph>
                        <paragraph>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see
 
  <content styleCode="bold">
                              <linkHtml href="#s26">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>and
 
  <content styleCode="bold">
                              <linkHtml href="#s23">OVERDOSAGE</linkHtml>
                           </content>sections).

 </paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s23">
               <id root="3417e20b-605f-3cdd-e063-6394a90ac707"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <effectiveTime value="20150910"/>
               <component>
                  <section ID="s24">
                     <id root="3418527b-c981-0189-e063-6294a90a1f6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Signs and Symptoms</content> ─ The toxic symptoms following an overdose of cefaclor may include nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an allergic reaction, or the effects of other intoxication.
 </paragraph>
                     </text>
                     <effectiveTime value="20150910"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="34186526-27e4-fa40-e063-6294a90af95f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Treatment</content>-- To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the 
  <content styleCode="italics">Physicians' Desk Reference (PDR).</content>In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
 </paragraph>
                        <paragraph>Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.</paragraph>
                        <paragraph>Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.</paragraph>
                        <paragraph>Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cefaclor.</paragraph>
                     </text>
                     <effectiveTime value="20120629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="34186f4c-e6bd-09b2-e063-6294a90a067b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Cefaclor is administered orally.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Adults</content> ─ The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Pediatric Patients</content> ─ The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours. In more serious infections, otitis media, and infections caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day.
 </paragraph>
                  <paragraph>Cefaclor may be administered in the presence of impaired renal function. Under such a condition, the dosage usually is unchanged (see 
  <linkHtml href="#s11">PRECAUTIONS</linkHtml>).
 </paragraph>
                  <paragraph>In the treatment of β-hemolytic streptococcal infections, a therapeutic dosage of cefaclor should be administered for at least 10 days.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20150910"/>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="34187c4e-90bb-1971-e063-6294a90ad698"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Cefaclor Capsule USP 250 mg (blue cap and pink body hard gelatin capsule containing white to slightly yellowish powder imprinted with ”KRC” on both capsule cap and capsule body) contains cefaclor USP (monohydrate) equivalent to 250 mg anhydrous cefaclor.</paragraph>
                  <paragraph>Bottle of 30     NDC 61442-171-30</paragraph>
                  <paragraph>Bottle of 100   NDC 61442-171-01</paragraph>
                  <paragraph>Bottle of 500   NDC 61442-171-05</paragraph>
                  <paragraph>Cefaclor Capsule USP 500 mg (blue cap and orange body hard gelatin capsule containing white to slightly yellowish powder imprinted with “KRC500” on both capsule cap and capsule body) contains cefaclor USP (monohydrate) equivalent to 500 mg anhydrous cefaclor.</paragraph>
                  <paragraph>Bottle of 30     NDC 61442-172-30</paragraph>
                  <paragraph>Bottle of 100   NDC 61442-172-01</paragraph>
                  <paragraph>Bottle of 500   NDC 61442-172-05</paragraph>
                  <paragraph>Store at 20 - 25℃ (68 to 77℉) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:
   <br/>
Yung Shin Pharmaceutical Ind. Co., Ltd.
  </content>
                     <br/>
Yung Shin Pharmaceutical Ind. Co., Ltd.
  <br/>
Tachia, Taichung 43769
  <br/>
TAIWAN
 </paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Distributed by:
   <br/>
Carlsbad Technology, Inc.
  </content>
                     <br/>
5922 Farnsworth Court,
  <br/>
Carlsbad, CA 92008, USA
 </paragraph>
                  <paragraph/>
                  <paragraph>Revised: 02/18</paragraph>
               </text>
               <effectiveTime value="20120629"/>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="3419f05c-757a-452d-e063-6394a90ad5d8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PRINCIPAL DISPLAY PANEL – 250mg Bottle Label</paragraph>
                  <paragraph>NDC 61442-171-05</paragraph>
                  <paragraph>CEFACLOR</paragraph>
                  <paragraph>Capsules USP</paragraph>
                  <paragraph>250 mg</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Carlsbad Technology, Inc.</paragraph>
                  <paragraph>500 Capsules</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3419f8dd-79c5-4992-e063-6394a90adae7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20150909"/>
               <component>
                  <observationMedia ID="img_3419f8dd-79c5-4992-e063-6394a90adae7">
                     <text>KRCy Label 500s 08-18</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="KRCy Label 500s 08-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s31">
               <id root="3419fd8f-1e26-57db-e063-6294a90a32b1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PRINCIPAL DISPLAY PANEL – 500mg Bottle Label</paragraph>
                  <paragraph>NDC 61442-172-05</paragraph>
                  <paragraph>CEFACLOR</paragraph>
                  <paragraph>Capsules USP</paragraph>
                  <paragraph>500 mg</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Carlsbad Technology, Inc.</paragraph>
                  <paragraph>500 Capsules</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3419fc45-9f52-5a74-e063-6294a90a72c0"/>
                  </paragraph>
               </text>
               <effectiveTime value="20150909"/>
               <component>
                  <observationMedia ID="img_3419fc45-9f52-5a74-e063-6294a90a72c0">
                     <text>KRCy5 Label 500s 08-18</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="KRCy5 Label 500s 08-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>